Claiming the Metabolite, Not the Drug A Deuterium Labelled Urate Blocker for Gout

This application claims a single chemical compound, a deuterium labelled relative of the old gout drug benzbromarone, together with the methods and compositions that use it to lower uric acid. Claim 1 is not a crystalline form and not a formulation. It is the molecule itself: (3,5-dibromo-4-hydroxyphenyl)(6-hydroxy-2-(1-hydroxyethyl)benzofuran-3-yl-4,5,7-d3)methanone, or a pharmaceutically acceptable salt or solvate of it. The applicant is Arthrosi Therapeutics, Inc. of San Diego, and the named inventors are Shunqi Yan, Litain Yeh, Rongzi Yan and Zancong Shen. It is a divisional of Australian application 2020274165.

The Problem

Gout is the most common form of inflammatory arthritis, and the specification describes it in one sentence: severe pain and tenderness in joints caused by urate crystals building up in and around them. The crystals form because the blood carries more uric acid than it can keep dissolved, a state called hyperuricemia, which the background attributes to either overproducing uric acid or under-excreting it. Most of the excretion happens in the kidney, and a transporter in the kidney tubule pulls filtered urate back into the blood rather than letting it go into the urine. Block that transporter and more urate leaves the body.

That is exactly what benzbromarone does, and the specification spends its opening pages on why benzbromarone is not the answer. It works. The background states that a single dose lowers serum uric acid, that levels keep falling with repeat dosing, and that chronic therapy can bring patients under the usual target of 6 mg/dL. But in a minority of patients it damages the liver badly, and the specification says a high proportion of those patients went on to acute liver failure leading to death or emergency liver transplant. It was never approved in the United States and was withdrawn in Europe in 2003.

The specification also names the chemistry behind the toxicity, which is the part that matters for this invention. The liver enzyme CYP2C9 hydroxylates benzbromarone at the 6 position of its benzofuran ring to give 6-hydroxybenzbromarone, described as the major metabolite. That is oxidised again to 5,6-dihydroxybenzbromarone, and then to a reactive ortho-quinone. The specification attributes the liver injury to this metabolic route and to the effect of those metabolites on mitochondria, citing published work by Iwamura and by Uchida. So the problem is not the scaffold. It is where the liver attacks the scaffold.

What This Invention Does

Claim 1 claims one compound. Read plainly, it is a benzofuran carrying a 6-hydroxy group and a 1-hydroxyethyl group, joined through a carbonyl bridge to a dibromo hydroxyphenyl ring, with the hydrogen atoms at ring positions 4, 5 and 7 replaced by deuterium. The claim covers that compound, its pharmaceutically acceptable salts and its solvates, and nothing else.

Paragraph [0014] of the description says what this molecule actually is: an active metabolite of a related tetradeuterated compound, (3,5-dibromo-4-hydroxyphenyl)(2-(1-hydroxyethyl)benzofuran-3-yl-4,5,6,7-d4)methanone. In other words the parent drug candidate carries deuterium at all four benzofuran ring positions, including position 6. When the liver hydroxylates position 6, that deuterium is lost and what remains is the compound claimed here, with three deuteriums and a hydroxyl. Arthrosi is claiming the breakdown product of its own molecule as an invention in its own right, which is a common and deliberate move in pharmaceutical filing.

The wider claim set follows the usual shape. Claims 2 to 14 cover two Markush genera, Formula (I) and Formula (II), in which four ring positions can each be hydrogen, deuterium, hydroxy or methoxy provided at least one is deuterium. Claims 15 to 37 are methods of treating or preventing gout or hyperuricemia by administering the compound, with dose brackets that narrow from about 3 mg to about 1500 mg down through about 10 mg to about 100 mg, oral dosing, with or without food, once or twice a day. Claims 33 to 37 add combination partners: a xanthine oxidase inhibitor such as allopurinol or febuxostat, and an SGLT2 inhibitor such as canagliflozin or empagliflozin. Claims 38 to 63 are pharmaceutical compositions over the same ground.

The biological evidence in the document is a single experiment, Example 3. MDCKII cells engineered to express the human URAT1 urate transporter were plated at 100,000 cells per well and grown for 24 hours. Uptake was run at 37 degrees C in Hank’s balanced salt solution without chloride at pH 7.4, with radiolabelled uric acid at 20 micromolar as the probe substrate and the test compound at seven concentrations from 0.01 to 10.0 micromolar, three wells each, solvent held at 1 per cent or less. The compound stayed in solution at every concentration tested, and it inhibited URAT1 mediated uric acid accumulation with an IC50 of 0.913 micromolar.

That single number is the whole of the pharmacology. There are no animal data, no pharmacokinetics, no liver safety data, and no side by side comparison against the non-deuterated compound or against benzbromarone. The specification never explains, in words, why deuterium was put on the ring, and it never uses the phrases isotope effect or metabolic stability. The reader has to infer the rationale from the benzbromarone metabolism discussion in the background.

Key Features

• One named compound as claim 1. The broadest claim is composition of matter over a single molecule, the 4,5,7-trideuterated, 6-hydroxy benzofuran ketone, plus its salts and solvates. No formulation limitation, no crystalline form, no particle size.
• Deuterium on the benzofuran ring. Three ring hydrogens are replaced by deuterium at positions 4, 5 and 7. Carbon to deuterium bonds break more slowly than carbon to hydrogen bonds, which is the standard reason deuterated drugs are made, though this specification does not say so.
• A metabolite claimed as an invention. The description identifies the claimed compound as an active metabolite of a tetradeuterated parent, so the filing protects what the body makes from the drug as well as the drug.
• A measured potency figure. In a cell assay expressing human URAT1, the compound inhibited uric acid uptake with an IC50 of 0.913 micromolar, and remained soluble across the tested range up to 10 micromolar.
• Dose brackets rather than a dose. The method and composition claims step down through five nested ranges, from about 3 mg to about 1500 mg at the widest to about 10 mg to about 100 mg at the narrowest, with the description adding a body weight basis of about 0.01 to 20 mg/kg per day.
• Named combination partners. Dependent claims cover co-administration with allopurinol, oxypurinol, febuxostat, topiroxostat or inositol, and separately with canagliflozin, dapagliflozin, empagliflozin or their fixed combinations with metformin or linagliptin.

Who Is Behind It

Arthrosi Therapeutics is a private biotechnology company founded in San Diego in 2018. Its own account of itself is that the founding team came out of Ardea Biosciences, where they worked on the first generation of urate transporter drugs before Ardea was bought by AstraZeneca. Two of the four named inventors on this application are the co-founders. Litain Yeh, the chief executive, was Vice President of Translational Sciences at Ardea and supervised the clinical pharmacology of lesinurad and verinurad, the two urate transporter inhibitors that company developed. Shunqi Yan, the chief operating officer, is a medicinal chemist whose profile lists work on enasidenib, ivosidenib and mitapivat. The specification itself names no inventor affiliations and gives no company background at all.

The company’s public pipeline is built on a single molecule, a once daily oral URAT1 inhibitor now called pozdeutinurad and previously AR882, which by 2026 was in two twelve month placebo controlled Phase 3 trials for progressive and tophaceous gout. Neither name appears anywhere in this specification, so the connection between the claimed metabolite and the clinical candidate is an inference from the chemistry rather than something the document states. On 9 February 2026, five weeks before this divisional was filed, Sobi announced that it had completed the acquisition of Arthrosi. The title page still records Arthrosi Therapeutics, Inc. as applicant.

On priority the specification is explicit, which is not always the case with divisionals. Paragraph [0001] states that the application is a divisional of Australian application 2020274165, which is the national phase entry of PCT/US2020/032725 filed 13 May 2020, which claims the benefit of United States provisional application 62/847,519 filed 14 May 2019. That makes the priority country the United States and the earliest priority date May 2019.

Why It Matters

Urate lowering therapy has been stuck for a long time. The first line drug, allopurinol, has been in use since the 1960s and works by cutting uric acid production rather than increasing its removal, and a large share of patients never reach target on it. The alternative approach, blocking reabsorption in the kidney, has a difficult history: benzbromarone was withdrawn over liver injury, and lesinurad, approved in the United States in December 2015, carried a kidney failure warning on its label and was discontinued by its manufacturer in 2019. That leaves a real clinical gap for patients whose uric acid stays high on standard treatment, and it explains why a company would go back to the benzbromarone scaffold at all rather than start from something new.

The deuterium strategy is a narrow and specific bet. It does not change what the molecule binds to or how tightly. It changes how fast one particular bond breaks. If the liver route that generates the reactive quinone starts with hydroxylation at the 6 position, then putting deuterium there is an attempt to slow that first step without touching the pharmacology. The compound claimed in this application is what the same route produces anyway, which is why claiming it separately makes sense: it is the species that will circulate in patients and contribute to the drug’s effect, and the dependent claims and the URAT1 assay treat it as active in its own right.

What a reader should take from the document is how thin the disclosure is relative to the claim. Composition of matter on a named molecule is the strongest kind of pharmaceutical claim, and here it is supported by two synthetic examples and one cell assay. That is enough to define the compound and show it does something at the target. It is not enough to show that the deuterium achieves anything, and the specification does not try. Whether the strategy works is a question the Phase 3 programme answers, not this filing.

Related Concepts

• Uric acid – the waste product whose blood concentration this compound is meant to reduce.
• Uricosuric – the drug class that lowers urate by increasing urinary excretion rather than blocking production.
• Kinetic isotope effect – the slower bond breaking that gives deuterium substitution its purpose, a rationale this specification never spells out.
• Benzofuran – the fused ring system at the centre of both benzbromarone and the claimed compound.
• Deuterium – the heavy hydrogen isotope placed at ring positions 4, 5 and 7 in claim 1.

---

AU 2026202224 was published in the Australian Official Journal of Patents on 9 April 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.